Anybody home? I see frothiness, floating crap, a rally which will likely take a breather. Lots of potential targets out there. TELK MDVN, ALNY, NBIX, THRM, OSIR, NUVO. Anybody got a favorite from this list? Mine is MDVN. I think Dimebon will fail as an Alzheimer's treatment. I'm just not sure how to time entry. If it works as well as cholinesterase inhibitors, and is fairly cheap, they'd have a place? IP is limited to a use patent. How strong is that? What prevents patients from simply buying Dimebon over the internet from Russia, patent or no patent? Await results and then short?
Message 23390189
No position in any of these yet, but getting an itchy trigger finger. Also open to other suggestions, or another point of view on the market's future.
I see a pullback in biotechs with the market, a run into ASCO by the cancer stocks, then the usual summer doldrums for most things. The wild card is the DNDN effect. But that should be more contained than it is. Provenge approval by no means signals a nicer FDA overall.
Cheers, Tuck |
